Down 44% over five years while the S&P 500 rose 74%.
“Third-quarter revenue fell short of our expectations, primarily due to lower biologics attachment,.”
ATEC's Quality Score rose 1 point on Tue, Nov 3, to 3.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Long-term trend | −2 |
| Latest filing | 8-K, Oct 29 |
After its last 4 reports it closed -19.1% on average, higher 1 of 4 times.
ATEC is #53 of 85 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 53 |
Expected to report Wed Feb 24, after the close (in 112 days). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A loss of $0.03 a share, from $0.19.
“Third-quarter revenue fell short of our expectations, primarily due to lower biologics attachment,”
ATEC's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| Total revenue | about $862M |
Sales grew 40% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 13% a year over 3 years.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Oct 29, 2026 | -39.7% | -38.1% | open |
| Aug 4, 2026 | -4.6% | -7.5% | -9.5% |
| May 5, 2026 | -21.7% | -31.7% | -24.3% |
Sales grew every year from 2018 to 2025, to $764M. It lost money in each of the eight years.
3 insiders bought $2M across 4 filings in the last 6 months. No open-market sales on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: ATEC is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others. Its procedural offerings are designed to address the underlying causes of spinal pathology by advancing the three fundamental objectives of spine surgery: (1) decompression of neural elements, (2) stabilization of spinal segments, and (3) restoration and maintenance of proper spinal alignment.
“Although we believe that our current broad product portfolio and development pipeline is differentiated and has numerous competitive advantages, the spinal implant industry is highly competitive, subject to rapid technological change, and significantly affected by new product introductions.”
ATEC scores 3 today, which Breakaway calls Below Average. It is #53 of 85 in Medical Devices by Quality Score, with 1 of 14 chart checks firing. Down 44% over five years while the S&P 500 rose 74%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
ATEC scores 3 today, which Breakaway calls Below Average (0 to 5). That is #53 of 85 in Medical Devices by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ATEC's 3.
3 insiders bought $2M across 4 filings in the last 6 months. No open-market sales on record. The newest is David M. Demski, Director, who bought $409K on Oct 30. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.